NBY
NovaBay Pharmaceuticals Inc
$
1.090
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.090
Open
1.050
VWAP
1.05
Vol
42.37K
Mkt Cap
138.61M
Low
1.020
Amount
44.46K
EV/EBITDA(TTM)
--
Total Shares
1.35M
EV
136.45M
EV/OCF(TTM)
33.23
P/S(TTM)
1.98
NovaBay Pharmaceuticals, Inc. is engaged in wound care products. The Company manufactures and sells its proprietary form of hypochlorous acid for the wound care market through its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
3.00M
+22.9%
-0.210
-64.65%
Estimates Revision
The market is revising No Change the revenue expectations for NovaBay Pharmaceuticals, Inc. (NBY) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 80.22%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+80.22%
In Past 3 Month
Valuation Metrics
The current forward P/E ratio for NovaBay Pharmaceuticals Inc (NBY.A) is -1.28, compared to its 5-year average forward P/E of -2.11. For a more detailed relative valuation and DCF analysis to assess NovaBay Pharmaceuticals Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-2.11
Current PE
-1.28
Overvalued PE
-0.39
Undervalued PE
-3.84
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-1.98
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.24
Undervalued EV/EBITDA
-3.71
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.90
Current PS
1.10
Overvalued PS
2.06
Undervalued PS
-0.26
Financials
Annual
Quarterly
FY2025Q3
YoY :
-78.66%
521.00K
Total Revenue
FY2025Q3
YoY :
+10.18%
-1.17M
Operating Profit
FY2025Q3
YoY :
+9.98%
-1.33M
Net Income after Tax
FY2025Q3
YoY :
-63.33%
-0.22
EPS - Diluted
FY2025Q3
YoY :
-14.69%
-1.76M
Free Cash Flow
FY2025Q3
YoY :
-87.65%
8.06
Gross Profit Margin - %
FY2025Q3
537.70
FCF Margin - %
FY2025Q3
YoY :
+384.39%
-240.50
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
23
163.1K
USD
Months
0-12
12
150.7K
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
23
163.1K
USD
Months
0-12
12
150.7K
USD
Months
NBY News & Events
Events Timeline
2025-10-20 (ET)
2025-10-20
19:09:19
NovaBay Meets NYSE American Continued Listing Requirements Again
2025-08-26 (ET)
2025-08-26
16:11:38
NovaBay announces special cash dividend of 80 cents per share
2025-08-19 (ET)
2025-08-19
17:26:50
NovaBay Signs $6M Securities Purchase Agreement with David Lazar
Sign Up For More Events
Sign Up For More Events
News
7.0
10-20NewsfilterNovaBay Pharmaceuticals, Inc. Meets NYSE American Continued Listing Requirements Again
8.5
10-03SeekingAlphaNovaBay submits $200M mixed securities registration statement
9.0
09-30BenzingaWolfspeed Shares Surge Over 50%; Check Out 20 Stocks Making Moves in Premarket Trading
Sign Up For More News
People Also Watch
FAQ
What is NovaBay Pharmaceuticals Inc (NBY) stock price today?
The current price of NBY is 1.09 USD — it has decreased -0.91 % in the last trading day.
What is NovaBay Pharmaceuticals Inc (NBY)'s business?
What is the price predicton of NBY Stock?
What is NovaBay Pharmaceuticals Inc (NBY)'s revenue for the last quarter?
What is NovaBay Pharmaceuticals Inc (NBY)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for NovaBay Pharmaceuticals Inc (NBY)'s fundamentals?
How many employees does NovaBay Pharmaceuticals Inc (NBY). have?